PGR and neoplasm: By contrast, a substantial absolute number of patients in TARGIT-A, just like the Fast-Forward trial of shorter-course whole breast radiotherapy (Table 2)12 were at higher risk of relapse: 1898 (83%) were younger than 70 years, 366 (16%) had tumours >2 cm in size, 443 (20%) patients had grade 3 cancers, 488 (22%) patients had involved nodes and 426 (19%) had ER- or PgR-negative tumours.